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http://www.clinicalepigeneticsjournal.com/content/6/1/2RESEARCH Open AccessDecitabine impact on the endocytosis regulator
RhoA, the folate carriers RFC1 and FOLR1, and the
glucose transporter GLUT4 in human tumors
David J Stewart1*, Maria I Nunez2, Jaroslav Jelinek3, David Hong2, Sanjay Gupta2, Jean-Pierre Issa3†,
Ignacio I Wistuba2† and Razelle Kurzrock4†Abstract
Background: In 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor
biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether
decitabine increased expression of various membrane transporters. Resistance to chemotherapy may arise due to
promoter methylation/downregulation of expression of transporters required for drug uptake, and decitabine can
reverse resistance in vitro. The endocytosis regulator RhoA, the folate carriers FOLR1 and RFC1, and the glucose
transporter GLUT4 were assessed.
Results: Pre-decitabine RhoA was higher in patients who had received their last therapy >3 months previously than
in patients with more recent prior therapy (P = 0.02), and varied inversely with global DNA methylation as assessed
by LINE1 methylation (r = −0.58, P = 0.006). Tumor RhoA scores increased with decitabine (P = 0.03), and RFC1 also
increased in patients with pre-decitabine scores ≤150 (P = 0.004). Change in LINE1 methylation with decitabine did
not correlate significantly with change in IHC scores for any transporter assessed. We also assessed methylation of
the RFC1 gene (alias SLC19A1). SLC19A1 methylation correlated with tumor LINE1 methylation (r = 0.45, P = 0.02).
There was a small (statistically insignificant) decrease in SLC19A1 methylation with decitabine, and there was a trend
towards change in SLC19A1 methylation with decitabine correlating with change in LINE1 methylation (r = 0.47,
P <0.15). While SLC19A1 methylation did not correlate with RFC1 scores, there was a trend towards an inverse
correlation between change in SLC19A1 methylation and change in RFC1 expression (r = −0.45, P = 0.19).
Conclusions: In conclusion, after decitabine administration, there was increased expression of some (but not other)
transporters that may play a role in chemotherapy uptake. Larger patient numbers will be needed to define the
extent to which this increased expression is associated with changes in DNA methylation.
Keywords: Decitabine, RhoA, RFC1, FOLR1, GLUT4, LINE1 methylation, Promoter methylationBackground
Resistance to chemotherapy can arise from overexpression
of resistance factors or from underexpression of factors
required for drug efficacy [1,2]. Dose–response curve flat-
tening at higher chemotherapy doses suggests that incur-
ability of epithelial malignancies may be due primarily to
underexpression of factors required for cytotoxicity [3]. If
resistance were instead due to overexpression of resistance* Correspondence: dstewart@toh.on.ca
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reproduction in any medium, provided the orfactors, one would expect a shoulder on a log-linear
dose–response curve (with increasing efficacy at higher
doses) instead of curve flattening at higher doses [1]. Ex-
amples of factors required for cytotoxicity that may be de-
ficient in resistant cells include drug uptake transporters
(for example, CTR1 for platinums and folate transporters
for pemetrexed), drug activating enzymes (for example,
deoxycytidine kinase for gemcitabine), obligate drug tar-
gets (for example, topoisomerase II for etoposide and
doxorubicin) and pro-apoptotic molecules [2,4,5].
Deficiency of factors required for drug uptake and ac-
tivation might directly potentiate resistance by reducingl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Stewart et al. Clinical Epigenetics 2014, 6:2 Page 2 of 9
http://www.clinicalepigeneticsjournal.com/content/6/1/2the amount of active drug in a cell, but could also have a
secondary effect, in that these transporters may also play
a role in uptake and cellular metabolism of nutrients.
Hence, deficiency in these factors could reduce the rate
of tumor cell division, and quiescent cells are generally
more resistant to chemotherapy than are actively dividing
cells [1,2,4]. Decreased uptake of several agents [6] and
downregulation of expression of various transporters in-
cluding folate binding protein and the endocytosis regula-
tor RhoA [7] has been described in cisplatin-resistant cells
that also have a reduced cell growth rate.
The mechanism by which transporters and other fac-
tors required for drug efficacy may be downregulated in
cancer cells remains unclear. However, promoter hyper-
methylation is one mechanism by which gene expression
may be downregulated, and hence DNA methylation
could play a role in underexpression of factors required
for drug efficacy [8-18]. Cancer cells often have abnor-
mal hypermethylation and silencing of tumor suppressor
genes [8-11] and of genes that support chemotherapy
cytotoxicity [12,13]. Several genes may be hypermethy-
lated in resistant cell lines [14,15] or tumors [18].
If DNA hypermethylation might play a role in resist-
ance, then it follows that agents that reduce DNA
methylation might sensitize cells to chemotherapy. The
DNA demethylating agent decitabine reversed folate
binding protein downregulation in cisplatin-resistant
cells [7], augmented cellular uptake of methotrexate and
carboplatin [7], and reversed resistance to various chemo-
therapy [15-17,19-24] or targeted agents [25] by upregu-
lating expression of proapoptotic factors [19,20,25] and by
other mechanisms [13]. DNA methylation also protected
the anti-apoptotic factor survivin from repression by p53,
and decitabine reversed this, permitting survivin repres-
sion by p53 [26]. Decitabine also partially reversed resist-
ance to carboplatin in patients with advanced ovarian
cancer [18,27,28].
The related DNA demethylating agent 5-azacytidine
downregulated telomerase expression [29] and potenti-
ated cisplatin [30-32], carboplatin [33], and docetaxel
[31,32,34] preclinically by decreasing expression of
pAKT [30,31] and other anti-apoptotic factors [31], by
increasing expression of the tumor suppressor gene
TMS1 [34] and various proapoptotic factors [31,33], and
by other mechanisms [30]. Also, 5-Azacytidine potenti-
ated irinotecan in p53-mutant cells by upregulating ex-
pression of its obligate target topoisomerase-I via
mechanisms involving p16 demethylation and Sp1 up-
regulation [35].
Decitabine is active clinically in myelodysplasia and
leukemia [36-38]. Low-dose administration days 1 to
5 +/− days 8 to 12 of a cycle may be most effective
[36-39]. Low-dose regimens are also particularly likely to
induce DNA demethylation [38,39].We administered low-dose decitabine days 1 to 5 +/−
days 8 to 12 each cycle to patients with refractory malig-
nancies and biopsied tumors before day 1 and on day 12
of cycle 1 [40]. In that study, decitabine decreased
methylation of the long interspersed nuclear element 1
(LINE1) repetitive element (which was used as a surro-
gate for ‘global’ tumor DNA methylation) and increased
tumor expression of the copper/platinum transporter
CTR1. Pre-decitabine tumor expression of CTR1 was
lower and LINE1 methylation tended to be higher in pa-
tients who were ≤3 months versus >3 months beyond
most recent prior therapy [40]. Decitabine’s impact on
CTR1 was greatest in patients more recently exposed to
other agents. CTR1 expression correlated inversely with
LINE1 methylation, although the CTR1 promoter was
not methylated [40].
Based on our observations with CTR1 [40], we then
asked whether other selected transporters behaved in a
similar manner in these same tumor specimens. Specific-
ally, we asked whether expression of other transporters
is decreased in tumors of patients recently exposed to
chemotherapy and targeted agents, whether tumor ex-
pression of transporters correlated inversely with LINE1
methylation, whether decitabine augmented transporter
expression, and whether promoter methylation could ex-
plain any impact of decitabine on expression of one of
these transporters.
Results
Patient characteristics
Patient characteristics have been reported in detail previ-
ously [40]. Tumor tissue was not available from all pa-
tients for all assessments, and hence patient numbers
varied across assessments. Patient numbers varied
slightly between different transporters since insufficient
biopsy material was available for some assessments. Of
the 31 patients treated on our decitabine trial [40], 27
had adequate tissue for at least one pre- or post-
decitabine IHC assessment of one or more transporters.
The 27 evaluable patients included 15 males and 12 fe-
males. Tumor types included cancers of the breast (four
patients), kidney (three), head and neck (four, including
two adenocystic carcinomas), lung (one), stomach (one),
endometrium (one), and appendix (one), malignant mel-
anomas (four), thymic neoplasms (three), neuroendo-
crine tumors (two), lymphomas (two), and desmoplastic
tumor (one). Patients had received a median (range) of 5
(1 to 14) prior systemic regimens and a median (range)
of 2 (0 to 6) prior targeted agents. Time from last prior
treatment until entry unto this study varied substantially
between patients. In patients with longer time intervals,
this was primarily a function of relatively prolonged con-
trol or indolent tumor growth after discontinuation of
their most recent prior therapy.
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Compared to other tumor types, adenocarcinomas had
higher pre-decitabine IHC scores for reduced folate car-
rier (RFC1) (median score 240 in adenocarcinomas ver-
sus 80 in others, P = 0.0096). Adenocarcinomas also had
a higher median pre-decitabine score for folate receptor-
alpha (FOLR1) (90 versus 60, P = 0.0146). There were no
major differences between adenocarcinomas and other
tumor types for pre-decitabine scores for the endocytosis
regulator/small GTPase RhoA (median scores 50 for
both adenocarcinomas and others, P = 0.7758) or for the
glucose transporter GLUT4 (median score 22.5 for
adenocarcinomas versus 10 for others, P = 0.52).
Transporter immunohistochemistry scores and time from
last therapy
Based on our previous observation that pre-decitabine
tumor IHC scores for CTR1 were significantly lower in
patients who were ≤3 months versus >3 months beyond
most recent prior chemotherapy or targeted therapy
[40], we assessed whether pre-decitabine tumor IHC
scores for other transporters were also higher in patients
>3 months beyond last prior therapy. Results varied with1-3 4-18
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Figure 1 Association of time from last prior treatment to tumor biop
expression (by IHC) for the small GTPase endocytosis regulator RhoA was h
(a, n = 18, median IHC score = 100 for patients with last prior therapy 4 to 1
months earlier, P = 0.02). Time from last prior therapy until pre-decitabine b
other transporters. For the folate transporter RFC1 (b, n = 19), the median s
and biopsy versus 135 for those with a 1 to 3 month interval (P = 0.06). For
both groups (P = 0.90). For the glucose transporter GLUT4 (d, n = 19), the m
therapy and biopsy versus 10 for those with a 1 to 3 month interval (P = 0.the transporter assessed (Figure 1). Tumor scores for
RhoA were higher in patients who had received their last
therapy >3 months versus ≤3 months previously (median
score 100 versus 30, P = 0.02), and correlated better with
time from last therapy if both targeted therapy and
chemotherapy were included (r = 0.24) than if only last
chemotherapy was included (r = 0.16). Conversely, there
was a trend towards tumor RFC1 scores being lower in
patients with last prior therapy >3 months versus
≤3 months earlier (42.5 versus 135, P = 0.06). Scores did
not vary with time from last therapy for FOLR1 (median
scores 80 versus 80, P = 0.90) or GLUT 4 (median scores
10 versus 15, P = 0.97).
Transporter immunohistochemistry scores versus LINE1
methylation (as a surrogate for global DNA methylation)
Based on our previous observation that tumor IHC
scores for CTR1 correlated inversely with LINE1 methy-
lation [40], we assessed whether pre-decitabine tumor
IHC scores for other transporters also correlated with
percent LINE1 methylation. Results again varied be-
tween transporters (Table 1). Pre-decitabine RhoA scores
correlated inversely with LINE1 methylation, while thereb
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sy with pre-decitabine immunohistochemistry (IHC) scores. Tumor
igher with longer time intervals between prior therapy and biopsy
8 months earlier versus 30 for patients with last prior therapy 1 to 3
iopsy did not have a significant impact on tumor expression of the
core was 42.5 for patients with 4 to 18 months between prior therapy
the folate transporter FOLR1 (c, n = 19), median scores were 80 for
edian score was 15 for patients with 4 to 18 months between prior
97).
Table 1 Correlation of pre-decitabine immunohistochemistry
(IHC) scores for transporters with percent LINE1 methylation
Transporter n Spearman r P
RhoA 21 −0.58 0.006
RFC1 22 0.004 0.99
FOLR1 22 −0.15 0.50
GLUT4 22 −0.009 0.70
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transporters.
Decitabine effect on transporter immunohistochemistry
scores
Based on our previous observation that tumor IHC
scores for CTR1 increased after treatment with decitabine
[40], we assessed whether tumor IHC scores for other
transporters also increased post-decitabine (Figure 2). Fol-
lowing decitabine therapy, RhoA increased in 14 of 18
evaluable patients, from a median score of 50 to a median
score of 77.5 (a relative increase of 55%, P = 0.03 by
Wilcoxon signed rank tests). The median increase was
slightly greater for patients whose last prior therapy was
≤3 months earlier than for patients whose last prior ther-
apy was >3 months before decitabine initiation (median
change 25 versus 10, P = 0.17).a
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Figure 2 Immunohistochemistry (IHC) scores for RhoA were significan
pre-decitabine biopsies. (a, n = 19, median scores 77.5 post-decitabine ve
P = 0.03). There was a trend towards higher scores in post-decitabine samp
scores 90 versus 90, with an increase in 14 of 21, P = 0.17). In patients with
scores with decitabine (c, n = 17, median scores 95 post-decitabine versus
P = 0.004). There was no increase with decitabine in scores for FOLR1 (d, n
P = 0.89) or for GLUT4 (e, n = 20, median scores 10 post-decitabine versus 5RFC1 scores increased in 14 of 21 evaluable patients
with decitabine therapy, although the median score
remained unchanged at 90 (P = 0.17). However, if only
patients with low pre-decitabine scores (<150) were
assessed, then RFC1 scores increased modestly in 13 of
17 patients (from a median score of 80 to a median
score of 90, P = 0.004). FOLR1 and GLUT4 scores did
not vary significantly with decitabine therapy. Change in
IHC scores did not vary significantly with decitabine
dose (data not shown).
Impact of decitabine on transporter IHC scores did not
appear to vary with tumor type. The changes in median
IHC scores with decitabine were 30 (adenocarcinomas)
versus 20 (others) for RhoA (P = 0.63), 30 (adenocarcin-
omas) versus 12 (others) for RFC1, -5 (adenocarcinomas)
versus 0 (others) for FOLR1 (P = 0.89) and 0 (adenocarcin-
omas) versus 0 (others) for GLUT4 (P = 0.96).
Post-decitabine changes in transporter
immunohistochemistry scores versus changes in LINE1
methylation
In our earlier studies in this patient group, changes in
tumor IHC scores for CTR1 did not correlate with
change in LINE1 methylation [40]. Similarly, changes in
IHC scores for other transporters did not correlate with
change in tumor LINE1 methylation for any transporter
assessed (Table 2).b
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tly higher in post-decitabine tumor biopsies compared to
rsus 50 pre-decitabine, with an increase in scores in 14 of 18 patients,
les compared to pre-decitabine samples for RFC1. (b, n = 21, median
pre-decitabine scores ≤150, there was a significant increase in RFC1
80 pre-decitabine, with an increase in RFC1 scores in 13 of 17 patients,
= 19, median scores 80 in both pre- and post-decitabine samples,
pre-decitabine, P = 0.61).
Table 2 Correlation of change in transporter
immunohistochemistry (IHC) scores with change in
percent LINE1 methylation
Transporter n Spearman r P
RhoA 20 −0.18 0.61
RFC1 19 0.22 0.37
FOLR1 17 −0.095 0.71
GLUT4 18 −0.18 0.48
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Since IHC scores for RFC1 increased over the course of
decitabine therapy in patients who initially had low
scores, we assessed promoter methylation for its gene
(alias SLC19A1) in patients with sufficient DNA. The
SLC19A1 assay (designed at the edge of the CpG island −
700 base pairs from the transcription start site) showed
median methylation of 64% (range, 21 to 83%) in pre-
decitabine tumor samples, compared to 18% in patient
blood samples, 10% in normal control adult blood sam-
ples, 9% in control umbilical cord blood samples, and
63% in leukemia cell lines. Median SLC19A1 methylation
was 57.5% in post-decitabine tumor samples (range, 19-
83%) (P = 0.63 in Wilcoxon signed rank test paired
comparisons for 10 patients with both pre- and post-
decitabine evaluable tumor samples). Changes in SLC19A1
methylation did not vary with decitabine dose (data not
shown).
SLC19A1 methylation correlated with LINE1 methyla-
tion in 26 evaluable pre- and post-decitabine tumor
samples (r = 0.45, P = 0.02), and there was a trend to-
wards change in SLC19A1 methylation varying with
change in tumor LINE1 methylation in patients (n = 11)
for whom both pre- and post-decitabine tumor samples
were evaluable for both genes (n = 11, r = 0.47, P =
0.1457). While RFC1 protein expression did not correl-
ate with SLC19A1 methylation across all evaluable
tumor samples (n = 24, r = −0.009, P = 0.97), there was a
trend towards change in RFC1 protein expression vary-
ing inversely with change in SLC19A1 methylation for
patients in who both pre- and post-decitabine tumor
samples were evaluable (n = 10, r = −0.45, P = 0.1912).
Discussion
In earlier studies, we found in patient tumor samples
that IHC scores for the copper/platinum transporter
CTR1 increased with increasing time from exposure to
last prior therapy [40], and we interpreted this as
possible evidence that prior therapy might induce cross-
resistance to platinums by downregulating CTR1, al-
though other explanations for our CTR1 observation are
possible. (For example, long time interval from last prior
therapy to decitabine might also have been due to indo-
lence of the patient’s tumor, and it is possible that highCTR1 expression could be a marker of tumor indolence
such that patients with high CTR1 tolerated longer time
intervals off therapy. However, in our earlier paper we
found that high CTR1 expression correlated with high
mitotic count [40], making this explanation unlikely). In
our earlier paper, we also noted that tumor CTR1 IHC
scores correlated inversely with LINE1 methylation (a
putative marker of global DNA methylation), and that
tumor CTR1 IHC scores increased after therapy with
the DNA demethylating agent decitabine [40]. Liang et al.
demonstrated a pleiotropic reduction in membrane trans-
porters in platinum-resistant tumor cell lines [6], and
Shen et al. reported that decitabine upregulated expres-
sion of a folate transporter and increased carboplatin and
methotrexate uptake in one of these cell lines [7]. Several
investigators demonstrated that decitabine or the related
DNA demethylating agent 5-azacytidine can reverse re-
sistance to chemotherapy in tumor cell lines, or can in-
duce changes that might reasonably be expected to
reverse resistance [13,19,20,25,26,29-31,33-35].
Based on these different lines of evidence, we hypothe-
sized that exposure to a wide range of chemotherapy
drugs or targeted agents might generate broad cross-
resistance by downregulating expression of a range of
unrelated membrane transporters. We further hypothe-
sized that this transporter downregulation could occur
through promoter hypermethylation and might be re-
versible by demethylating agents. Our findings from the
current study failed to confirm our hypothesis. While
our findings with the endocytosis regulator RhoA were
very similar to our previous observations with CTR1,
the other transporters behaved differently. Like CTR1
[40], RhoA scores varied inversely with LINE1 methyla-
tion and increased with time from last therapy exposure
and with decitabine treatment, and others have reported
that RhoA gene hypermethylation was associated with
reduced RhoA expression in human tumors [41]. How-
ever, unlike CTR1 [40] and RhoA, scores for the trans-
porters RFC1, FOLR1 and GLUT4 did not increase with
time from last drug exposure and did not vary inversely
with LINE1 methylation, although RFC1 did increase
modestly with decitabine. Hence, exposure to a wide
range of agents could potentially lead to a limited
spectrum of cross-resistance by downregulating expres-
sion of some specific transporters, and decitabine could
potentially increase expression of some transporters, but
not others. It remains untested whether decitabine can
reverse resistance to agents that rely on these trans-
porters for uptake into tumor cells.
On the other hand, while a broad downregulation of
transporters was not noted in our study patients with re-
cent prior therapy exposure, we cannot comment on
transporter function, and there are other factors that
could come into play in limiting drug uptake. Specifically,
Table 3 Antibodies used for immunohistochemistry
Protein Antibody type Source Dilution
RFC1/SLC19A1 Polyclonal (antibody 62302) Abcam, Cambridge, MA, USA 1:100
FOLR1 Monoclonal IgG, clone Mb343 Homemade, kindly supplied by Dr. Wilbur Franklin [55] 1:500
GLUT4 Polyclonal Abcam, Cambridge, MA, USA 1:1000
RhoA Monoclonal Novus Biologicals, Littleton, CO, USA 1:250
Table 4 Primers used for pyrosequencing assessments of
SLC19A1 methylation
Step Name Sequence
PCR1 RFC1F1 AGGGATAAGTATAGTTTGTTTTTGGGGAT
PCR1 RFC1R AATAACCCAAACCCCCCTTCC
PCR1 RFC1RU GGGACACCGCTGATCGTTTAATAACCCAAACCCCCCTTCC
PCR2 RFC1F2 GTGATTAGTAAGGGTTTGTATTAAGGAGTAAG
PCR2 BioUni [Biotin]GGGACACCGCTGATCGTTTA
PSQ RFC1S TAGTTTTTATTTTAGTAGGGATAG
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plasma membrane protein recycling has been noted in
cisplatin-resistant cell lines [6], and this in turn was linked
to defective endocytosis and to down-regulation of small
GTPases including RhoA [7]. Hence, down-regulation of
the small GTPases might potentially be sufficient to de-
crease uptake of a range of agents, and restoring RhoA
and related factors could possibly reverse this, even if
there is no obvious impact on expression of transporters.
The mechanism by which decitabine increased CTR1
scores (in our previous study [40]) and RhoA and RFC1
(in the present study) is not clear. Decitabine can in-
crease expression of specific genes through mechanisms
that are both dependent on [9] and independent of
[9,11] promoter hypermethylation. We found no evi-
dence of CTR1 promoter hypermethylation in our previ-
ous study [40]. In the current study, we did find
promoter methylation of the RFC1 gene (alias SLC19A1),
but there was only a modest reduction in SLC19A1 pro-
moter methylation with decitabine. Furthermore, RFC1
scores did not correlate with SLC19A1 methylation, al-
though there was a trend towards change in SLC19A1
methylation correlating with change in RFC1 score.
The reduced folate carrier is the major uptake medi-
ator of anticancer antifolates and silencing of the re-
duced folate carrier gene (through a mechanism that
appeared to be independent of promoter methylation)
was noted in multiple resistant tumor cell lines [42]. Ex-
posure of cell lines to methotrexate downregulated
expression of RFC1, and this was not prevented by 5-
azacytidine [43]. Since folic acid insufficiency alters
DNA methylation [44], since there is an inverse relation-
ship between folate levels and DNA methylation in hu-
man tumors [45], and since folic acid supplementation
appears to induce DNA hypomethylation [46,47] in
some circumstances (possibly by decreasing production
of S-adenosylmethionine, the methyl donor for DNA
methyltransferase) [47], it would also be of interest to
assess whether addition of folic acid augments the ability
of decitabine to induce DNA hypomethylation and re-
store silenced gene function. If decitabine can increase
uptake of folate into tumors by increasing RFC1 expres-
sion, then folic acid and decitabine could possibly po-
tentiate each other’s effects.
Overall, our observations suggest that it would be rea-
sonable to test decitabine clinically in combination withother agents (including antifolates and platinums) to de-
termine if it can prevent or reverse resistance that arises
due to reduced drug uptake, and the experience to date
in platinum-resistant ovarian cancer is encouraging
[18,27,28]. It might be particularly useful to test its ability
to potentiate chemotherapy in patients with low baseline
expression of RhoA, RFC1 and/or CTR1, in those with
higher baseline LINE1 methylation, and/or in those with a
shorter time interval since last prior therapy. As noted pre-
viously, there are also several other mechanisms by which
demethylating agents may prevent or reverse resistance to
a variety of agents [7,13,14,19-21,25,26,29-31,33-35].
However, addition of decitabine to other agents could
also have adverse consequences. For example, while we
previously reported that decitabine therapy was associ-
ated with increased apoptosis in human tumors, we also
found that mitoses and Ki-67 expression tended to in-
crease with decitabine administration in tumors in
which they were initially low [40] (suggesting that deci-
tabine possibly might stimulate proliferation of quiescent
tumor cells). While this might increase sensitivity of qui-
escent tumors to chemotherapy, it could also lead to re-
sistance through accelerated repopulation. Furthermore,
others have demonstrated that decitabine may reduce
tumor cell sensitivity to cisplatin by reversing promoter-
methylation-induced downregulation of the resistance
factor glutathione-S-transferase-pi [48] and demethylating
agents also increased tumor cell expression of resistance-
associated drug efflux pumps, including MDR1/p-glyco-
protein [49,50]. While some studies have suggested that
DNA demethylation may increase efficacy of topoisomerase-
1 inhibitors [35], others suggested that decitabine-induced
DNA hypomethylation reduced camptothecin’s ability to
induce DNA strand breaks [51]. The related agent 5-
azacytidine augmented expression of the DNA repair
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and thereby decreased tumor cell sensitivity to radiation
[52]. Tumor cell expression of metallothioneins (which
may be important in chemotherapy resistance [4]) was
also reduced by promoter methylation and augmented by
5-azacytidine [53].
Conclusions
In summary, decitabine administration was associated
with biological changes in human tumors that could
prove therapeutically useful, particularly if decitabine is
combined with other agents. However, as we have ar-
gued previously for anticancer therapies in general [54],
the broad range of decitabine’s potential effects mean
that in future studies we should use extensive molecular
characterization of patients’ tumors to carefully assess
which patients are most likely to be helped versus
harmed by decitabine use.
Methods
Patients and methods
As previously reported [40], eligibility criteria for this
study (approved by the University of Texas MD Anderson
Cancer Center Research Ethics Board) included written,
informed consent, diagnosis of incurable malignancy re-
fractory to standard therapy, adequate organ function, and
tumor amenable to biopsy. Decitabine (supplied under a
Collaborative and Research Development Agreement by
the National Cancer Institute Division of Cancer Treat-
ment and Diagnosis) was administered intravenously over
one hour [40]. Doses were 2.5, 5, or 10 mg/m2/day on days
1 to 5 and 8 to 12 each 4-week cycle or 15 or 20 mg/m2/
day on days 1 to 5 each cycle. Filgrastim was added at
higher doses.
Patients had tumor biopsies pre-decitabine and day 12,
cycle 1 [40]. IHC was assessed using formalin-fixed,
paraffin-embedded 5 μm-thick tissue sections that were
deparaffinized and hydrated, then stained with mouse
antibodies against RohA, RFC1, FOLR1 [55], and
GLUT4 (Table 3). Envision Plus Dual Link-labeled poly-
mer (Dako, Inc, Carpinteria, CA, USA) was used as the
secondary antibody. Staining intensity was scored as 0 to
3+, then multiplied by the percent of tumor cells stain-
ing to give an IHC score of 0 to 300. Changes in IHC
scores were calculated by subtracting the day 1 score
from the day 12 score.
Percentage of DNA CpG islands that were methylated
was assessed by LINE1 assays as a surrogate for global
DNA methylation as previously described [56] and re-
ported [40]. Change in LINE1 methylation was calcu-
lated (day 12 value minus day 1 value divided by day 1
value). Promoter methylation for SLC19A1 (the gene en-
coding RFC1) was assessed by bisulfite pyrosequencing
[57], using primers described in Table 4.Non-parametric two-tailed statistics were calculated
using GraphPad Prism 5.0 (Spearman tests for correla-
tions, Wilcoxon signed rank tests for paired compari-
sons, and Mann–Whitney tests for comparisons of two
groups). Low patient numbers limited statistical power.
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